中外科學家共同發佈人類基因編輯技術「底線」北京新浪網 (2017-02-15)中新社北京2月15日電 (記者 張素)記者15日從中國科學院獲悉,由22位科學家組成的人類基
Pages
Thursday, February 16, 2017
(人類基因編輯峰會) 生殖細胞/胚胎 基因編輯 須 治療/預防 嚴重疾病 !!
科妍 膀胱灌注液 獲醫材classIII許可證
個股:科妍(1786)泌尿科用產品海優樂膀胱灌注液取得第3類
成大 信用卡 繳醫療費 (醫美&健檢 例外)
全台第一家! 成大醫學中心可刷卡繳費 2017-02-15 16:09聯合報 記者修瑞瑩╱即時報導 成大醫院即日起開放就診民眾可以刷卡繳交醫療費用,
杏輝(李易達) 注重人才! 生技營 產業好朋友
杏輝生技營 持續培育產業人才 2017-02-15跨領域的人才培訓是生技產業未來發展的重要
疾管署: ….99名H5N6相關接觸者均健康良好
H5N6禽傳人風險雖低,國內家禽相關工作人員仍須做好自我防護 資料來源:疾病管制署 建檔日期:2017/02/14 更新時間:2017/02/14因應國內H5N6高病原性禽流感
陳建仁副總統: 將鬆綁法規 加強新藥研發審查過程
陳建仁:鬆綁法規 帶動台灣生醫產業 【大紀元2017年02月15日訊】副總統陳建仁今天接見「
追憶「台灣核子醫學之父」葉鑫華
神隆 開發 Fondaparinux (52步驟)搶市: 手術後防血栓 (2016年送FDA/ 2018預上市)
神隆「雙A」策略 切入學名藥用原料藥 2017-02-15 20:18經濟日報 記者黃文奇╱即時報導 台灣神隆(1789)15日公告2016年財報,稅後純益為6.
翁啟惠: …愛台灣/ 檢方: …貢獻與本案無關!!
浩鼎案 翁啟惠出庭為「愛台灣」落淚 2017-02-15 22:30經濟日報 記者黃文奇╱即時報導 浩鼎案起訴,15日首度開庭,
神隆 積極轉型: 新藥代客研發 & 學名藥製劑 & 優化原料藥
神隆營運穩定 去年每股賺0.87元 2017-02-15 10:55中央社 台北15日電 提供原料藥及製劑開發製造的台灣神隆公布2016年自行結算財報
(翁啟惠 辯護律師)…台湾生技产业的愿景
浩鼎开庭翁启惠落泪 律师批检方张冠李戴 【新唐人2017年02月15日讯】
(浩鼎案开庭) 境管….阻碍推广台湾学术发展 !
台浩鼎案开庭 律师谈名誉翁启惠闻言拭泪 【大纪元2017年02月15日讯】
盛弘+中國恆大集團 布局” 十三五” 醫管 商機 !!
盛弘去年營收新高 今年聚焦醫療服務 2017-02-16 〔記者陳永吉/台北報導〕屬於敏盛醫院體系的盛弘醫藥(8403
光鼎生技 多元基因檢測 僅需3-5分鐘 !
光鼎單一檢測平台 滿足多元基因檢測 2017年02月16日 04:10 台北訊 光鼎生技在分子生物醫學檢測市場策略,將以Qsep100單一平
鴻海集團 全球防疫 召集人: 尹彙文醫師
郭董把科技導入公衛醫療 2017-02-16 04:04經濟日報 記者尹慧中/台北報導 從廠區到社區,鴻海董事長郭台銘看到高科技的兩個新應用領域,
敏成 (盛弘) 2017Q2申請上櫃: 布局 高階熔噴濾材/醫療/運動休閒
盛弘醫導入創新平台 今年經營拚起飛 2017-02-15 14:51中央社 台北15日電 盛弘醫藥去年營收創掛牌來新高,董事長楊弘仁表示,
盛弘醫療 集團 西藥 使用250億元 !!
盛弘醫療互聯網平台 吸引逾5千醫師加入 2017年02月15日 13:53 杜蕙蓉 盛弘董事長楊弘仁表示,醫療互聯網時代來臨,
疾管署 嚴正回應 社論 ”拿出抗煞精神迎戰禽流感”
防疫視同作戰,
臺灣動藥 編製 小動物腫瘤學 書 !
臺灣動藥 延續寵物新生命 2017年02月15日 04:10 王奕勛 台灣動藥董事長陳建宏表示,公司首支寵物抗癌用藥獲美國FDA肯
(驚人相似) 乳腺幹細胞 & 三陰性乳腺癌亞型
乳癌研究新突破 墨科學家發現特殊幹細胞 【大紀元2017年02月15日訊】(
(JAMA: UK Biobank 基因揭密) Belly Fat, abdominal adiposity腹部肥胖/ Waist-to-Hip Ratio --糖尿病/心臟病關係
基因傾向「蘋果型」身材 易患糖尿或心臟病 2017-02-15 12:02中央社 邁阿密14日綜合外電報導研究人員今天表示,
Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes One study author recommends greater use of the waist-to-hip ratio in practice to prevent disease in high-risk patients. By Yael L. Maxwell February 14, 2017 Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes New genetic evidence is supporting the idea that people who are predisposed to carrying fat in their belly as opposed to their hips and thighs are also at greater risk for developing heart disease and type 2 diabetes. Prior observational studies have linked abdominal adiposity with cardiometabolic disease, but it has remained unclear whether it plays a causal role. For their analysis published today in JAMA, Connor Emdin, DPhil (Massachusetts General Hospital, Boston, MA), and colleagues constructed a polygenic risk score of 48 single-nucleotide polymorphisms (SNPs) for waist-to-hip ratio adjusted for body mass index (BMI). Applying this score to individual-level data from the UK Biobank, they found higher risks of type 2 diabetes (OR 1.77; 95% CI 1.57-2.00) and coronary heart disease (OR 1.46; 95% CI 1.32-1.62) associated with each standard deviation increase in waist-to-hip ratio. As for why this might be, those with higher waist-to-hip ratios seemed to have higher levels of triglycerides, 2-hour glucose, and systolic blood pressure (P < 0.001 for all). "The relationship to heart disease and diabetes did not surprise us," senior author Sekar Kathiresan, MD (Massachusetts General Hospital), told TCTMD, noting however that he and his colleagues "were a little surprised" that the level of triglycerides in the blood could explain the relationship between belly fat and disease risk. There are a number of different theories that could clarify this, he said, but "the abdominal fat cells seem to secrete a lot of bad factors that go into the blood and that actually lead to delayed clearance of the fat from the blood, which [leads] to higher levels of triglyceride-rich lipoproteins." While there is definitely "something about the visceral fat is different from the fat that is in the thighs and hips," further research is needed to clarify it, Kathiresan observed. "It's a completely fertile ground, because there's very little known about what the factors are that lead to the apple shape versus the pear shape. And it's hard to model in organisms, like mice for example, because they just have a totally different body fat distributions than humans." In his experience, physicians often focus more on overall weight or BMI in their patients, and not specifically where the fat is stored. But the waist-to-hip ratio is "an easily available marker for who is at particularly [high] risk for diabetes and heart disease," Kathiresan said, advising clinicians to pay more attention to it in practice. For the long term, understanding the genetics "that actually change the body fat distribution away from abdominal adiposity . . . may actually be as beneficial as focusing on the overall weight," potentially leading to the development of safe and effective medications for weight loss, he said.
Championing Mendelian Randomization In an accompanying editorial, George Davey Smith, MD, DSc, Lavinia Paternoster, PhD, and Caroline Relton, PhD (University of Bristol, England), suggest that the current study could serve as an example for future avenues of investigation. Mendelian randomization—the reliance on how genes are randomly assigned without bias as a basis for clinical research and what Emdin et al used in their study—"can be considered analogous to randomization in an RCT," they argue. Early studies "tended to use single genetic variants and focus on a specific risk factor-disease association within a single study population," they explain. Now, however, "large numbers of genetic variants [are] being identified for many exposures." Given the causal relationship between abdominal adiposity and heart disease/diabetes shown in this study, "such conditional measures are likely to become increasingly adopted in studies in the future, as more complex aspects of disease causation are investigated," the editorialists predict. Smith, Paternoster, and Relton point out that reducing obesity through public health efforts and interventions has proven to be difficult, so it would make sense that specifically targeting belly fat would be even more challenging. "Abdominal adiposity is shown to influence several such mediators in the report by Emdin et al, and triglyceride levels were demonstrated to be potentially important with respect to CHD risk," they write. "A formal Mendelian randomization mediation analysis could be applied that would more robustly quantify the contribution of potentially treatable intermediaries, and targeting such could have important public health benefit." Looking at recent studies, the editorialists suggest that attention to Mendelian randomization could have "prevented very expensive late-stage clinical trial failures. . . . Indeed, the adoption of Mendelian randomization to prioritize (or deprioritize) major investment in RCTs before their inception should be actively encouraged."
Sources Emdin CA, Khera AV, Natarajan P, et al. Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease. JAMA. 2017;317:626-634. Smith GD, Paternoster L, Relton C. When will Mendelian randomization become relevant for clinical practice and public health? JAMA. 2017;317:589-591.
Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease JAMA. 2017;317(6):626-634. doi:10.1001/jama.2016.21042 Question Is genetic evidence consistent with a causal relationship among waist-to-hip ratio adjusted for body mass index (a measure of abdominal adiposity), type 2 diabetes, and coronary heart disease? Findings In this mendelian randomization study, a polygenic risk score for increased waist-to-hip ratio adjusted for body mass index was significantly associated with adverse cardiometabolic traits and higher risks for both type 2 diabetes and coronary heart disease. Meaning These results provide evidence supportive of a causal association between abdominal adiposity and the development of type 2 diabetes and coronary heart disease.
Importance In observational studies, abdominal adiposity has been associated with type 2 diabetes and coronary heart disease (CHD). Whether these associations represent causal relationships remains uncertain.
Objective To test the association of a polygenic risk score for waist-to-hip ratio (WHR) adjusted for body mass index (BMI), a measure of abdominal adiposity, with type 2 diabetes and CHD through the potential intermediates of blood lipids, blood pressure, and glycemic phenotypes.
Design, Setting, and Participants A polygenic risk score for WHR adjusted for BMI, a measure of genetic predisposition to abdominal adiposity, was constructed with 48 single-nucleotide polymorphisms. The association of this score with cardiometabolic traits, type 2 diabetes, and CHD was tested in a mendelian randomization analysis that combined case-control and cross-sectional data sets. Estimates for cardiometabolic traits were based on a combined data set consisting of summary results from 4 genome-wide association studies conducted from 2007 to 2015, including up to 322 154 participants, as well as individual-level, cross-sectional data from the UK Biobank collected from 2007-2011, including 111 986 individuals. Estimates for type 2 diabetes and CHD were derived from summary statistics of 2 separate genome-wide association studies conducted from 2007 to 2015 and including 149 821 individuals and 184 305 individuals, respectively, combined with individual-level data from the UK Biobank.
Results Among 111 986 individuals in the UK Biobank, the mean age was 57 (SD, 8) years, 58 845 participants (52.5%) were women, and mean WHR was 0.875. Analysis of summary-level genome-wide association study results and individual-level UK Biobank data demonstrated that a 1-SD increase in WHR adjusted for BMI mediated by the polygenic risk score was associated with 27-mg/dL higher triglyceride levels, 4.1-mg/dL higher 2-hour glucose levels, and 2.1–mm Hg higher systolic blood pressure (each P < .001). A 1-SD genetic increase in WHR adjusted for BMI was also associated with a higher risk of type 2 diabetes (odds ratio, 1.77 [95% CI, 1.57-2.00]; absolute risk increase per 1000 participant-years, 6.0 [95% CI, CI, 4.4-7.8]; number of participants with type 2 diabetes outcome, 40 530) and CHD (odds ratio, 1.46 [95% CI, 1.32-1.62]; absolute risk increase per 1000 participant-years, 1.8 [95% CI, 1.3-2.4]; number of participants with CHD outcome, 66 440).
Conclusions and Relevance A genetic predisposition to higher waist-to-hip ratio adjusted for body mass index was associated with increased risk of type 2 diabetes and coronary heart disease. These results provide evidence supportive of a causal association between abdominal adiposity and these outcomes.
(辭董事) 台達電 無法給 環瑞醫 營運意見/ 供應鏈仍維持 !
台達電辭環瑞醫董事 持股19.55%不會出脫 2017-02-15 11:53經濟日報 記者劉怡妤╱即時報導 台達電(2308)公告辭任轉投資公司環瑞醫(4198)董事,